Executive Summary
replicate bioscience Learn about where we work around the globe Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates.
Replicate Bioscience stands at the forefront of a revolutionary wave in medicine, leveraging its proprietary self-replicating RNA (srRNA) technology to develop groundbreaking therapeutic and vaccine candidatesReplicate Bioscience Overview, Address & Contact This innovative approach amplifies the power of RNA, offering novel treatment opportunities across a spectrum of diseases, from infectious agents to complex conditions like cancer and metabolic disordersReplicate Bioscience isdeveloping RNA-based treatments for cancerusing proprietary Synthetic Replicon for gene delivery (SynRGY) technology to deliver the The company's commitment to advancing global health is evident in its diverse applications and strategic collaborationsReplicate's off-the-shelf srRNAs contain two components: virally derived genetic code to drive controlled and self-limiting amplification, and
At its core, Replicate Bioscience is developing RNA-based treatments for cancer and other serious illnessesJacqueline Lim Posy, Molecular Biology BS '06 MS '08, was part of the research team that developed the novel vaccine technology going into Their unique srRNA technology is engineered to deliver genetic instructions for protein production within the bodyReplicate has engineered viral RNAto deliver instructions for making proteins, such as antibodies and cytokines, to treat conditions including Unlike traditional mRNA therapies, Replicate's off-the-shelf srRNAs contain two components: virally derived genetic code that drives controlled and self-limiting amplification, and the therapeutic payloadReplicate Bioscience: Home This inherent self-amplifying nature allows for significantly lower effective doses, a key advantage often referred to as dose-sparing by approximately 10-fold compared to conventional mRNAJacqueline Lim Posy, Molecular Biology BS '06 MS '08, was part of the research team that developed the novel vaccine technology going into This efficiency not only reduces the amount of material needed but also contributes to a more durable and potent biological responseReplicate Bioscienceis pioneering novel self-replicating RNA (srRNA) technology to enable more treatment opportunities for more people.
The efficacy and potential of Replicate's srRNA vaccine have been demonstrated, with initial clinical studies showing it elicited a protective immune response that met the WHO threshold for protection at unparalleled low dosesReplicate Bioscience, Inc. - Drug pipelines, Patents This remarkable achievement underscores the power and precision of their platformReplicate Bioscience, Inc. The durability of next-generation self-replicating RNA vaccine candidates is a significant area of ongoing research and development for the companyReplicate Bioscience isdeveloping RNA-based treatments for cancerusing proprietary Synthetic Replicon for gene delivery (SynRGY) technology to deliver the
Replicate Bioscience has strategically partnered with leading organizations to expand the reach and impact of its technologyNovo Nordisk seeks new obesity, diabetes drugs with A notable collaboration is with Novo Nordisk, a global leader in diabetes and obesity careReplicate Biosciencewants to replicate the success RNA technology has had in responding to the COVID-19 pandemic but with self-replicating RNAs to go after This alliance, initiated in August 2025, aims to advance self-replicating RNA therapies for obesity and type 2 diabetesTogether, we'll advance ourself-replicating RNA (srRNA) technologyfor obesity, type 2 diabetes, and cardiometabolic disease. A milestone moment for RNA The partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for these prevalent cardiometabolic diseasesReplicate Bioscience and Instituto Butantan Enter This collaboration signifies a major step forward, with California biotech Replicate Biosciences set to receive substantial funding from Novo Nordisk to develop new drugs targeting these conditionsReplicate Bioscience, Inc. As part of this agreement, Replicate Bioscience will partner with Novo Nordisk to expedite the development of these innovative treatmentsDurability of next-generation self-replicating RNA vaccine
Beyond metabolic diseases, Replicate Bioscience is actively engaged in developing treatments for infectious diseases and oncologyReplicate Bioscience Announces Partnership with Novo The company has been awarded significant grants, including approximately $7 million from the Gates Foundation, to utilize its srRNA platform to develop malaria and HIV candidatesReplicate Bioscience, Inc. - Drug pipelines, Patents Furthermore, significant funding, such as the $40 million series A round secured in September 2021, has propelled the development of a portfolio of preclinical projects employing self-replicating RNA (srRNA)Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious
The company's scientific expertise is rooted in its ability to precisely engineer viral RNAReplicate Bioscience, Inc. Replicate has engineered viral RNA to deliver instructions for making specific proteins, such as antibodies and cytokines, which are crucial for treating a variety of conditionsReplicate Bioscience partners with Novo Nordiskto advance self-replicating RNA therapies for obesity and type 2 diabetes, This sophisticated approach allows for targeted therapeutic interventions and the creation of potent vaccine candidatesCalifornia biotech Replicate Bioscienceswill receive up to 0 million from Novo Nordisk in an alliance that aims to track down new drugs
Replicate Bioscience, IncReplicate Bioscience and Instituto Butantan Enter , headquartered in San Diego, CA, USA, is a clinical-stage company with a clear vision for the future of medicineReplicate Bioscience - Duke OTC Their commitment extends to understanding and addressing urgent issues in global health, global development, and education, as they learn about where we work around the globeReplicate Bioscience will partner with Novo Nordiskto develop treatments using self-replicating RNA technology for obesity, type 2 diabetes The company's pipeline is robust, encompassing a range of therapeutic areas including infectious disease, oncology, autoimmune disease, and moreMessage delivery: Replicate Bioscience closes M Through continuous innovation and strategic alliances, Replicate Bioscience is poised to redefine the landscape of RNA therapeutics and deliver life-changing solutions to patients worldwideReplicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious
Related Articles
Frequently Asked Questions
Here are the most common questions about replicate bioscience.
Leave a Comment
Share your thoughts, feedback, or additional insights on this topic.
